Clinical Trial Evaluating the Efficacy and Safety of Uracil 0,5% Plasters in Oncology Patients Affected by Hand-foot Syndrome (HFS)

Inclusion Criteria

* Both sexes;
* Aged over 18 years;
* Willing and able to return to the study site for post-procedural assessments;
* Agree to take precautions to prevent pregnancy (applicable only to non-menopausal female subjects), including abstinence, intrauterine device (IUD), progestin implants, combined estrogen-progestin contraceptives, or condom use;
* Agree to sign the informed consent form.
* With HFS of grade I and II severity due to chemotherapy Self-sufficient with Performance Status of 0, 1, 2 according with the EOCG table.
* Red blood cells folate test and serum folate test- Independent Biomarkers performed and to polymorphism testing DPD before starting therapy with dihydro pyrimidines.

Exclusion criteria

* Patients with grade III severity according to of HFS severity (Hand-Foot Syndrome- NCI-CTCAE v.0 Severity Grading.
* ECOG Performance Status Scale = 3 or 4
* Pregnancy (applicable only to non-menopausal female subjects);
* Breastfeeding (applicable only to non-menopausal female subjects);
* Non-menopausal female subjects not using the specified contraceptive measures to prevent pregnancy during the study;
* Sensitivity or allergy to the investigational product or its components (to be assessed by the investigator at baseline);
* Predicted poor compliance with study protocol;
* Participation in a similar study currently or within the past 3 months;
* Dermatological clinical conditions that could interfere with performance outcomes;
* Current pharmacological treatment with:

  * Medications that may affect test results as deemed by the investigator.
  * Use of other medications not mentioned above can be authorized by the investigator. Trade name, dosage, start and end dates of therapy will be documented in the concomitant medication form.